NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
Clinical Trials
13 trialsNCT04074564 2023-10-23
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase EARLY_PHASE1 Unknown
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04296370 2020-08-10
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03267654 2020-08-03
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT04383977 2020-05-12
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03245307 2018-02-07
A Study To Test The Effect Of Apatinib On P450 Enzymes
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03243643 2017-09-08
HS:Hansoh;
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03026881 2017-03-07
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT02332512 2017-02-24
ANSWER
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown